<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04898686</url>
  </required_header>
  <id_info>
    <org_study_id>B3002020000086</org_study_id>
    <nct_id>NCT04898686</nct_id>
  </id_info>
  <brief_title>Probiotic Chewables in Allergic Rhinoconjunctivitis Patients</brief_title>
  <official_title>Study of the Probiotic Potential of a Lacticaseibacillus Strain in the Upper Airways in Patients With Allergic Rhinoconjunctivitis After Administration in a Chewable</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Antwerp</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>DSM Nutritional Products, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Antwerp</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      With this double- blind, randomised, placebo-controlled study, we want to investigate the&#xD;
      influence of a chewable with the probiotic strain Lacticaseibacillus rhamnosus GG on the&#xD;
      symptoms and immunological markers of allergic rhinoconjunctivitis (AR). In addition, we aim&#xD;
      to investigate the influence of this probiotic chewable on the microbiome of the upper&#xD;
      respiratory tract after administration in adults with AR. The bacterial and cytokine profiles&#xD;
      in the naso- and oropharynx will be monitored before, during and after the treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>double blind, randomized, placebo controlled</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Transfer of L. rhamnosus GG to the oronasopharyngeal cavity after administration of the chewable</measure>
    <time_frame>at 8 weeks</time_frame>
    <description>qPCR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in the score of allergic rhinitis symptoms</measure>
    <time_frame>over the study period (= 10 weeks)</time_frame>
    <description>Daily questionnaires will be used, in which a self-reported Total Nasal Symptom Score (TNSS) based on rhinorrhea, nasal congestion, nasal itching and sneezing with symptom severity ranging from 0 to 12 will be recorded.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>changes in microbiome of the oronasopharyngeal region after administration of the chewable</measure>
    <time_frame>start, 8 weeks</time_frame>
    <description>16S rRNA amplicon sequencing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inlfuence on general nose- and mouth health</measure>
    <time_frame>start, 8 weeks, 10 weeks</time_frame>
    <description>A clinical evaluation by an ENT specialist will be performed at the start and 8 weeks of the study to assess the general nose and mouth health of the participants. Questions on discomfort and symptoms of inflammation or infection in the nose and mouth will be included in the SNOT-22-based questionnaire implemented at the start, week 8 and week 10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the absolute numbers of specific airway pathogens and viruses</measure>
    <time_frame>start, 8 weeks</time_frame>
    <description>qPCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in cytokine levels (e.g. IL-10, IL-4, IL-5, IL-13) in oro- and nasopharynx samples, and cytokine and antibody levels in blood samples</measure>
    <time_frame>start, 8 weeks</time_frame>
    <description>qPCR and/or ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of medication use</measure>
    <time_frame>over the study period (= 10 weeks)</time_frame>
    <description>Daily questionnaires will be used where the type and frequency of medication use should be recorded</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Allergic Rhinoconjunctivitis</condition>
  <arm_group>
    <arm_group_label>Probiotic group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>daily use of a probiotic chewable for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>daily use of the placebo chewable for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Probiotic chewables</intervention_name>
    <description>chewables containing Lacticaseibacillus rhamnosus GG</description>
    <arm_group_label>Probiotic group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo chewables</intervention_name>
    <description>chewables without probiotic strain. Ingredients: Xylitol, microcrystalline cellulose, stearic acid, natural orange flavor, silica, magnesium stearate, citric acid and malic acid.</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults aged 18 at the time of registration;&#xD;
&#xD;
          -  Seasonal allergic rhinoconjunctivitis (AR) in the context of grass pollen allergy&#xD;
             diagnosed on the basis of anamnesis cfr. ARIA guidelines and positive skin prick test&#xD;
             and / or immunocap assay;&#xD;
&#xD;
          -  Positive skin prick test (SPT) for grass pollen and / or the presence of specific IgE&#xD;
             for grass pollen, confirmed by a medical specialist, measured at the start of the&#xD;
             study: Soluprick SQ Phleum pratense pollen 10 HEP - ALK and / or IgE specific&#xD;
             immunocap assay Phleum pratense (timothy grass) (g6);&#xD;
&#xD;
          -  Body Mass Index in the range of 19-32 kg / m2;&#xD;
&#xD;
          -  Instructed during screening and agreed not to use other probiotic products outside of&#xD;
             the study during the study period;&#xD;
&#xD;
          -  Signed the consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Antibiotic use at baseline and during the study;&#xD;
&#xD;
          -  Pregnant women;&#xD;
&#xD;
          -  Unstable / uncontrolled asthma (to be determined by investigator-physician);&#xD;
&#xD;
          -  Sensitization to dust mites&#xD;
&#xD;
          -  History of probiotic use in the past two weeks;&#xD;
&#xD;
          -  Current diagnosis of cancer or immunosuppressive therapy within the past 6 months;&#xD;
&#xD;
          -  Abnormalities of the oral mucosa;&#xD;
&#xD;
          -  Acute and chronic infectious and inflammatory upper airway diseases (eg acute /&#xD;
             chronic rhinosinusitis cfr. EPOS guidelines);&#xD;
&#xD;
          -  Clinically significant bleeding disorder;&#xD;
&#xD;
          -  Any other medical condition that, in the principal investigator's opinion, warrants&#xD;
             exclusion from the trial;&#xD;
&#xD;
          -  History of regular use (&gt; 3 days out of 7) of tobacco products within the previous two&#xD;
             weeks&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sarah Lebeer, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universiteit Antwerpen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Olivier Vanderveken, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Antwerp</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sarah Lebeer, Prof</last_name>
    <phone>+3232653285</phone>
    <email>sarah.lebeer@uantwerpen.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Olivier Vanderveken, Prof</last_name>
    <phone>+3238213384</phone>
    <email>olivier.vanderveken@uza.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Antwerp University Hospital</name>
      <address>
        <city>Edegem</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier Vanderveken, Prof</last_name>
      <phone>+3238213384</phone>
      <email>olivier.vanderveken@uza.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 28, 2021</study_first_submitted>
  <study_first_submitted_qc>May 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2021</study_first_posted>
  <last_update_submitted>May 19, 2021</last_update_submitted>
  <last_update_submitted_qc>May 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Antwerp</investigator_affiliation>
    <investigator_full_name>Sarah Lebeer</investigator_full_name>
    <investigator_title>Prof. dr.ir.</investigator_title>
  </responsible_party>
  <keyword>lactobacilli</keyword>
  <keyword>microbiome</keyword>
  <keyword>probiotic chewables</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Conjunctivitis, Allergic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

